Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Pipeline Review, H2 2017 Summary According to the recently published report 'Methionine Aminopeptidase 2 - Pipeline Review, H2 2017'; Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Methionine aminopeptidase 2 is an enzyme that in humans is encoded by the METAP2 gene. Methionine aminopeptidase 2 is a member of the dimetallohydrolase family is a cytosolic metalloenzyme that catalyzes the hydrolytic removal of N-terminal methionine residues from nascent proteins. Increased expression of this METAP2 is associated with various forms of cancer, and the anti-cancer drugs fumagillin and ovalicin inhibit the protein by irreversibly binding to its active site. Inhibitors of METAP2 have shown to be effective for the treatment of obesity. The report 'Methionine Aminopeptidase 2 - Pipeline Review, H2 2017' outlays comprehensive information on the Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Oncology, Immunology, Cardiovascular, Genetic Disorders, Infectious Disease and Ophthalmology which include indications Obesity, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Prostate Cancer, Solid Tumor, Inflammation, Malaria, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Prostate Cancer, Osteosarcoma, Prader-Willi Syndrome (PWS), Pulmonary Hypertension, Rheumatoid Arthritis, Type 2 Diabetes and Uveitis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - The report reviews Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics and enlists all their major and minor projects - The report assesses Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Overview 7 Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 11 Products under Development by Universities/Institutes 14 Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Therapeutics Assessment 16 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Companies Involved in Therapeutics Development 20 Asieris Pharmaceuticals Co Ltd 20 Chong Kun Dang Pharmaceutical Corp 20 Merck KGaA 21 SynDevRx Inc 21 Takeda Pharmaceutical Co Ltd 22 Zafgen Inc 22 Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Drug Profiles 23 APL-1301 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 beloranib - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 lodamin - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 M-8891 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 nitroxoline - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 RSF-101 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 SDX-7195 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 SDX-7320 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Small Molecules to Inhibit MAP2 for Obesity - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Small Molecules to Inhibit MetAP2 for Inflammation and Obesity - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Small Molecules to Inhibit MetAP2 for Metabolic Disorders - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Small Molecules to Inhibit METAP2 for Oncology, Obesity, Rheumatoid Arthritis, Malaria and Pulmonary Hypertension - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 ZGN-1061 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Dormant Products 47 Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Discontinued Products 49 Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Product Development Milestones 50 Featured News & Press Releases 50 Sep 12, 2017: Zafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes 50 Sep 12, 2017: Zafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes 51 Jun 10, 2017: Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association's 77th Annual Scientific Sessions 51 Jun 06, 2017: Zafgen to Present Two Late-Breaking Abstracts for ZGN-1061 at the American Diabetes Association 77th Scientific Sessions 53 May 04, 2017: Zafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor 53 Mar 09, 2017: Zafgen Provides Update on ZGN-1061 54 Sep 20, 2016: Zafgen Initiates Multiple Ascending Dose Cohorts in Phase 1 Clinical Trial of ZGN-1061 55 Jul 19, 2016: Zafgen Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061 56 Jun 11, 2016: Zafgen Presents New Data from the Phase 2b Clinical Trial Evaluating Beloranib in Severe Obesity Complicated by Type 2 Diabetes at the American Diabetes Associations 76th Scientific Sessions 57 Apr 03, 2016: Zafgen Presents New Data from the Phase 3 bestPWS Study Evaluating Beloranib in Prader-Willi Syndrome at ENDO 2016 59 Mar 28, 2016: Zafgen to Present Data from bestPWS Study of Beloranib in Prader-Willi Syndrome at ENDO 2016 61 Feb 18, 2016: Zafgen's Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint 62 Jan 20, 2016: Zafgen's Pivotal Phase 3 Trial of Beloranib in Prader-Willi Syndrome Achieves Co-Primary Efficacy Endpoints 63 Dec 02, 2015: Zafgen Announces Beloranib IND Placed on Complete Clinical Hold 65 Dec 02, 2015: Zafgen Provides Clinical Update on Beloranib 65 Appendix 66 Methodology 66 Coverage 66 Secondary Research 66 Primary Research 66 Expert Panel Validation 66 Contact Us 66 Disclaimer 67
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indication, H2 2017 10 Number of Products under Development by Companies, H2 2017 11 Products under Development by Companies, H2 2017 12 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13 Number of Products under Investigation by Universities/Institutes, H2 2017 14 Products under Investigation by Universities/Institutes, H2 2017 15 Number of Products by Stage and Mechanism of Actions, H2 2017 16 Number of Products by Stage and Route of Administration, H2 2017 18 Number of Products by Stage and Molecule Type, H2 2017 19 Pipeline by Asieris Pharmaceuticals Co Ltd, H2 2017 20 Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 20 Pipeline by Merck KGaA, H2 2017 21 Pipeline by SynDevRx Inc, H2 2017 21 Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 22 Pipeline by Zafgen Inc, H2 2017 22 Dormant Products, H2 2017 47 Dormant Products, H2 2017 (Contd..1), H2 2017 48 Discontinued Products, H2 2017 49
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
